Scientists found that inhibiting a regulatory protein alters the intricate signaling chemistry that is responsible for many of the disease’s symptoms. The findings provide a path to possible therapeutics for disorders associated with Fragile X.
Scientists found that inhibiting a regulatory protein alters the intricate signaling chemistry that is responsible for many of the disease’s symptoms. The findings provide a path to possible therapeutics for disorders associated with Fragile X.